Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 (RMD Open, 2017)

(untitled) - Coates, L; Kishimoto, M; Gottlieb, A; Shuler, C; Lin, C; Lee, C; Mease, P